🇺🇸 XL184 in United States

480 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pyrexia — 61 reports (12.71%)
  2. Sepsis — 55 reports (11.46%)
  3. Diarrhoea — 52 reports (10.83%)
  4. Dyspnoea — 51 reports (10.62%)
  5. Fatigue — 46 reports (9.58%)
  6. Malignant Neoplasm Progression — 45 reports (9.38%)
  7. Acute Kidney Injury — 43 reports (8.96%)
  8. Nausea — 43 reports (8.96%)
  9. Anaemia — 42 reports (8.75%)
  10. Dehydration — 42 reports (8.75%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is XL184 approved in United States?

XL184 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for XL184 in United States?

Exelixis is the originator. The local marketing authorisation holder may differ — check the official source linked above.